Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - sildenafil citrate, quantity: 28.09 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; triacetin - revatio is used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of revatio has not been evaluated in patients currently on bosentan therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ciprofloxacin hydrochloride, quantity: 832.5 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; maize starch; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - c-flox is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections- bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. c-flox is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered. consideration should be given to available official guidance on the appropriate use of antibacterial agents.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ciprofloxacin hydrochloride, quantity: 555 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: crospovidone; pregelatinised maize starch; maize starch; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - c-flox is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. c-flox is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered. consideration should be given to available official guidance on the appropriate use of antibacterial agents.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ciprofloxacin hydrochloride, quantity: 277.5 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; maize starch; crospovidone; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - for the treatment of infections caused by susceptible organisms in the following conditions: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity.- inhalational anthrax (post-exposure). to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note:1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. c-flox is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered. consideration should be given to available official guidance on the appropriate use of antibacterial agents.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 35.12 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; croscarmellose sodium; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of erectile dysfunction in adult males. it is not indicated for use by women.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 140.48 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of erectile dysfunction in adult males. it is not indicated for use by women.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 35.12 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; croscarmellose sodium; hyprolose; titanium dioxide; indigo carmine aluminium lake; lactose monohydrate; hypromellose; triacetin - treatment of erectile dysfunction in adult males. it is not indicated for use by women.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 70.24 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; hyprolose; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; indigo carmine aluminium lake; lactose monohydrate; hypromellose; triacetin - treatment of erectile dysfunction in adult males. it is not indicated for use by women.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 70.24 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of erectile dysfunction in adult males. it is not indicated for use by women.